RWDD3 抗体
Quick Overview for RWDD3 抗体 (ABIN7118740)
抗原
See all RWDD3 抗体适用
宿主
克隆类型
标记
应用范围
-
-
原理
- RWDD3 antibody
-
纯化方法
- Immunogen affinity purified
-
纯度
- ≥95 % as determined by SDS-PAGE
-
免疫原
- RWD domain containing 3
-
亚型
- IgG
-
-
-
-
应用备注
- IHC: 1:20-1:200
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
注意事项
- Avoid repeated freeze / thaw cycles.
-
储存条件
- -20 °C
-
储存方法
- -20°C for 12 months
-
有效期
- 12 months
-
-
- RWDD3 (RWD Domain Containing 3 (RWDD3))
-
别名
- RWDD3
-
背景
-
Synonyms: RWD domain-containing protein 3|RWD domain-containing sumoylation enhancer (RSUME)|RWDD3|RSUME
Background: Enhancer of SUMO conjugation. Via its interaction with UBE2I/UBC9, increases SUMO conjugation to proteins by promoting the binding of E1 and E2 enzymes, thioester linkage between SUMO and UBE2I/UBC9 and transfer of SUMO to specific target proteins which include HIF1A, PIAS, NFKBIA, NR3C1 and TOP1. Isoform 1 and isoform 2 positively regulate the NF-kappa-B signaling pathway by enhancing the sumoylation of NF-kappa-B inhibitor alpha(NFKBIA), promoting its stabilization which consequently leads to an increased inhibition of NF-kappa-B transcriptional activity. Isoform 1 and isoform 2 negatively regulate the hypoxia-inducible factor-1 alpha(HIF1A) signaling pathway by increasing the sumoylation of HIF1A, promoting its stabilization, transcriptional activity and the expression of its target gene VEGFA during hypoxia. Isoform 2 promotes the sumoylation and transcriptional activity of the glucocorticoid receptor NR3C1 and enhances the interaction of SUMO1 and NR3C1 with UBE2I/UBC9. Has no effect on ubiquitination.
-
基因ID
- 25950
-
UniProt
- Q9Y3V2
抗原
-